Tatva Chintan Pharma Chem logo

Tatva Chintan Pharma Chem financials and balance sheet

NSE: TATVABSE: 543321Chemicals & PetrochemicalsSmall Cap

Last close ₹1,569.30down ₹94.80 (5.70%)BSE ₹1,572.10

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,664.10.

52-week range of traded prices to 23 Oct 2026
₹1,044.10Low, 30 Mar 2026₹2,113.60High, 21 Oct 2026
Market cap
₹3,671 Cr999th largest listed
P/E
58.3
P/B
4.5
Dividend yield
0.13%
ROE
8.0%
ROCE
8.8%
Debt to equity
0.21
Volume, NSE
2,50,09037.5% delivered

5 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Tatva Chintan Pharma Chem annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹506 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue506
  2. Materials and goods−225
  3. Employee costs−63
  4. Other expenses−125
  5. Operating profit93
  6. Depreciation−37
  7. Other income+3.5
  8. One-off items0.0
  9. Finance costs−2.9
  10. Profit before tax57
  11. Tax−15
  12. Net profit42

What the company owns

  • Plant, investments and other assets₹680 Cr
  • Inventory₹196 Cr
  • Receivables₹119 Cr
  • Cash and bank₹9 Cr

What pays for it: net worth and liabilities

  • Net worth₹782 Cr
  • Borrowings₹120 Cr
  • Owed to suppliers₹58 Cr
  • Other liabilities₹43 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Tatva Chintan Pharma Chem quarterly results

₹ croreMar 2022Filed 26 AprMar 2023Filed 8 MayMar 2024Filed 11 MayMar 2025Filed 10 JunMar 2026Filed 16 May
Revenue from operations434424394383506
325363325349413
Materials and goods bought195226174199225
Employee costs3139555363
Other expenses100989697125
Operating profit before depreciation10861683493
Operating margin25.0%14.3%17.3%8.9%18.4%
Materials, % of revenue44.9%53.4%44.3%52.0%44.4%
Employee costs, % of revenue7.1%9.1%13.9%13.8%12.4%
Other expenses, % of revenue23.0%23.2%24.5%25.3%24.8%
Depreciation and amortisation810262837
Operating profit after depreciation1005143756
Other income96824
Finance costs58713
Profit before one-off items and tax1044844857
One-off items0−4000
Profit before tax1044544857
8−113215
Net profit964530642
Other comprehensive income01013
Total comprehensive income964630645
Net margin22.1%10.7%7.7%1.5%8.3%

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2022Filed 26 AprMar 2023Filed 8 MayMar 2024Filed 11 MayMar 2025Filed 10 JunMar 2026Filed 16 MaySep 2026Half yearFiled 19 Oct
473515737739782815
Share capital222223232323
Reserves451493714715758791
1201701436120170
1712368096213296
1452199
Total assets6587568198361,0041,119
222443521571654650
436314298265350469
Net debt−57125−3422112155
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2022Filed 26 AprMar 2023Filed 8 MayMar 2024Filed 11 MayMar 2025Filed 10 JunMar 2026Filed 16 MaySep 2026Half yearFiled 19 Oct
2028982531−4
393710829391
−75−2836−8−62−73
Receivables34−3115−15−22−64
Inventories−9871019−62−53
Payables−3−1311−132033
Other working capital−88−12211
Tax paid−18−9−10−4−8−4
Capital spending892031297611431
Free cash flow−69−175−30−52−82−35
−197−101−121−65−116−31
2353831177940
Dividends paid045525
Shares bought back000000
Shares issued2110197000
Net change in cash59−368−24−55
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Tatva Chintan Pharma Chem dividend history

₹ per shareMar 2022Filed 26 AprMar 2023Filed 8 MayMar 2024Filed 11 MayMar 2025Filed 10 JunMar 2026Filed 16 May
Earnings per share₹44.59₹20.52₹13.26₹2.44₹17.98
Diluted earnings per share₹44.59₹20.52₹13.26₹2.44₹17.98
Dividend per share₹2.00₹2.00₹2.00₹1.00₹2.00
Book value per share₹213.44₹232.25₹315.10₹315.84₹334.20
Dividend payout4.6%9.7%15.4%40.9%11.1%
Shareholder yield−4.1%0.1%−7.6%0.3%0.1%
Market cap at the year end (₹ crore)5,1173,6992,5231,5842,462
RatioMar 2022Filed 26 AprMar 2023Filed 8 MayMar 2024Filed 11 MayMar 2025Filed 10 JunMar 2026Filed 16 May
Revenue growth–−2.3%−7.1%−2.7%32.2%
Operating profit growth–−44.0%12.6%−49.8%172.3%
Net profit growth–−52.6%−33.3%−81.2%636.1%
Earnings per share growth–−54.0%−35.4%−81.6%636.9%
20.3%9.2%4.8%0.8%5.5%
–−11.1 pts−4.4 pts−4.1 pts4.8 pts
From the net margin–−10.4 pts−2.6 pts−3.9 pts3.5 pts
From asset turnover–−0.9 pts−1.1 pts−0.1 pts0.8 pts
From borrowing–0.3 pts−0.7 pts−0.1 pts0.4 pts
Return on capital employed16.9%7.4%5.7%0.8%6.2%
Cash conversion21.3%61.1%323.0%431.8%74.9%
Interest cover20.76.16.55.119.8
Debt to equity0.250.330.020.050.15
Receivable days4873657986
Inventory days319262320246319
Payable days8352946095
Cash conversion cycle, days283283291264310
Working capital days164171170183175
Asset turnover0.660.600.500.460.55
Assets per rupee of net worth1.391.431.261.121.21
Sales per rupee of plant2.722.160.920.730.84
Capital spending to depreciation10.9021.265.022.763.09
Plant being built, % of plant in use32.3%117.9%17.1%4.1%3.9%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.6%
Cash from operations against operating profit
33.8%
Measure5 years3 years
Revenue growth, yearly rate–6.1%
Profit growth, yearly rate–−2.6%
Return on equity, average8.1%3.7%
Return on capital employed, average7.4%4.3%
Operating margin, average16.8%14.9%
Net margin, average10.1%5.8%
Asset turnover, average0.550.50
Cash conversion cycle, days, average286288
Interest cover, average11.610.5
Debt to equity, average0.160.07

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations20215431
Cash from investing−600−302−116
Cash from financing39912679
Capital spending611319114
Dividends paid16122
Shares bought back000
Shares issued for cash4081970
Borrowings raised––85
Borrowings repaid40121

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––656
Altman Z-scorePublished threshold 1.8119.2211.0220.7711.698.58
Beneish M-scorePublished threshold −1.78–−0.92−3.17−2.65−2.56
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–16.806.715.5913.74
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––0.851.851.97
Receivables growth less revenue growthOur threshold 0 percentage points–51.44−10.1320.8912.06
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−20.5516.97−26.5333.51
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−2.471.272.02−1.79
Assets under construction, years of additionsOur threshold 2 years of additions–5.010.280.170.20
Effective tax ratePublished threshold 17.16 per cent7.92−1.5830.3324.6226.23
Tax charged less tax paid, % of profitOur threshold 10 percentage points−9.76−22.337.70−34.7312.76
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 Sep 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil A2+Review, Upgrade10.50
8 Sep 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil A-Review, UpgradeStable220
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.